RT Journal Article
SR Electronic
T1 Feasibility of <sup>99m</sup>Tc-MIP-1404 for SPECT/CT Imaging and Subsequent PSMA-Radioguided Surgery in Early Biochemically Recurrent Prostate Cancer: A Case Series of 9 Patients
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 59
OP 62
DO 10.2967/jnumed.122.263892
VO 64
IS 1
A1 Koehler, Daniel
A1 Sauer, Markus
A1 Klutmann, Susanne
A1 Apostolova, Ivayla
A1 Lehnert, Wencke
A1 Budäus, Lars
A1 Knipper, Sophie
A1 Maurer, Tobias
YR 2023
UL http://jnm.snmjournals.org/content/64/1/59.abstract
AB This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA)–radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: Nine patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median, 747 MBq; interquartile range [IQR], 710–764 MBq) 17.2 h (IQR, 16.9–17.5 h) before SPECT/CT and 22.3 h (IQR, 20.8–24.0 h) before RGS. Results: Seventeen PSMA-positive lesions were detected on PET/CT (median short-axis diameter, 4 mm; IQR, 3–6 mm; median SUVmax, 8.9; IQR, 5.2–12.6). Nine of 17 (52.9%) were visible on SPECT/CT (median SUVmax, 13.8; IQR, 8.0–17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background level (median count, 31; IQR, 17–89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared with PET/CT. Prostate-specific antigen values decreased after RGS in 6 of 9 patients (67%). Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients, including 2 additional lesions compared with PET/CT.